Skip to main content
SpringerLink
Log in

Heparin Therapy

Regimens and Treatment Considerations

  • Practical Therapeutics
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Heparin is a parenteral antithrombotic agent with efficacy in the treatment and prevention of venous thromboembolic disease and in preinfarctional angina. Accumulating evidence also suggests that heparin is useful in the prevention of coronary artery reocclusion after thrombolytic therapy for acute myocardial infarction, and in the prevention of left ventricular mural thrombosis after anterior wall myocardial infarction. Heparin appears to offer only marginal benefit in reducing mortality when given in combination with thrombolytic therapy and aspirin for acute myocardial infarction.

When used for prevention of venous thromboembolism in moderate risk patients, heparin should be given subcutaneously in a dose of 5000U every 12 hours for 5 to 7 days or until the patient is ambulatory. In higher risk patients, such as those undergoing total hip replacement, heparin should be given subcutaneously every 12 hours in a dose to prolong the activated partial thromboplastin time (aPTT) by 4 to 5 seconds into the upper normal range.

When used to treat active venous thromboembolism or the peri-infarctional state, heparin should be given by intravenous infusion with loading and maintenance doses to consistently prolong the aPTT to between 1.5- and 2.5-fold the control value (mean of laboratory’s normal range). If constant intravenous infusion is not possible, the drug should be given subcutaneously every 12 hours to consistently prolong the aPTT between 1.5 and 2.5 times control. This regimen is also recommended in pregnant women with venous thromboembolic disease or mechanical heart valves.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Alpert JS, Smith R, Carlson CJ, et al. Mortality in patients treated for pulmonary embolism Journal of the American Medical Association 236: 1477–1480, 1976

    Article  PubMed  CAS  Google Scholar 

  • Altman R, Rouvier J, Gurfinkel E, et al. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. Journal of Thoracic and Cardiovascular Surgery 101: 427–431, 1991

    PubMed  CAS  Google Scholar 

  • Andersson S, Fagrell B, Holmgren K, et al. Subcutaneous administration of heparin: a randomised comparison with intravenous administration of heparin to patients with deep vein thrombosis. Thrombosis Research 27: 631–639, 1982

    Article  PubMed  CAS  Google Scholar 

  • Ansell J, Deykin D. Heparin-induced thrombocytopenia and recurrent thromboembolism. American Journal of Hematology 8: 325–332, 1980

    Article  PubMed  CAS  Google Scholar 

  • Ansell J, Slepchuk N Jr, Kumar R, et al. Heparin-induced thrombocytopenia: a prospective study. Thrombosis and Haemostasis 43: 61–65, 1980

    PubMed  CAS  Google Scholar 

  • Babcock KB, Dumper CW, Scharfman WB. Heparin-induced thrombocytopenia. New England Journal of Medicine 295: 237–241, 1976

    Article  PubMed  CAS  Google Scholar 

  • Barradell LB, Buckley MM. Nadroparin calcium. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs 44: 858–888, 1992 (this issue)

    Article  PubMed  CAS  Google Scholar 

  • Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled clinical trial. Lancet 1: 1309–1312, 1960

    Article  PubMed  CAS  Google Scholar 

  • Basu D, Gallus A, Hirsh J, et al. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. New England Journal of Medicine 287: 325–327, 1972

    Article  Google Scholar 

  • Beguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thrombosis and Haemostasis 60: 457–462, 1988

    PubMed  CAS  Google Scholar 

  • Bell WR, Royall RM. Heparin-induced thrombocytopenia: a comparison of three heparin preparations. New England Journal of Medicine 303: 902–907, 1980

    Article  PubMed  CAS  Google Scholar 

  • Bentley PG, Kakkar VV, Scully MF, et al. An objective study of alternative methods of heparin administration. Thrombosis Research 18: 177–187, 1980

    Article  PubMed  CAS  Google Scholar 

  • Bell WR, Tomasulo PA, Alving BM, et al. Thrombocytopenia occurring during the administration of heparin: a prospective study in 52 patients. Annals of Internal Medicine 85: 155–160, 1976

    PubMed  CAS  Google Scholar 

  • Bjornsson TO, Wolfram BS, Kitchell BB. Heparin kinetics determined by three assay methods. Clinical Pharmacology Therapy 31: 104–113, 1982

    Article  CAS  Google Scholar 

  • Blajchman MA, Young E, Ofosu FA. Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits. Annals of the New York Academy of Science 556: 245–254, 1989

    Article  CAS  Google Scholar 

  • Bleich SD, Nichols T, Schumacher R, et al. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. American Journal of Cardiology 66: 1412–1417, 1990

    Article  PubMed  CAS  Google Scholar 

  • Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. New England Journal of Medicine 313: 1369–1375, 1985

    Article  PubMed  CAS  Google Scholar 

  • Chiu HM, Hirsh I, Yung WL, et al. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 49: 171–184, 1977

    PubMed  CAS  Google Scholar 

  • Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. New England Journal of Medicine 316: 581–589, 1987

    Article  PubMed  CAS  Google Scholar 

  • Coon WW, Willis PW III, Symons MJ. Assessment of anticoagulant therapy of pulmonary thromboembolism. Annals of Surgery 197: 559–568, 1969

    Article  Google Scholar 

  • Cruickshank MK, Levine MN, Hirsh J, Roberts R, Siguenza M. A standard heparin monogram for the management of heparin therapy. Archives of Internal Medicine 151: 333–337, 1991

    Article  PubMed  CAS  Google Scholar 

  • De Bono DP, Simoons ML, Tijssen J, et al. Early intravenous heparin improves coronary patency in thrombolysis with recombinant human tissue-type plasminogen activator. British Heart Journal 67: 122–128, 1992

    Article  PubMed  Google Scholar 

  • Doyle DJ, Turpie AG, Hirsh J, et al. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis: a randomized trial. Annals of Internal Medicine 107: 441–445, 1987

    PubMed  CAS  Google Scholar 

  • Dukes GE Jr, Sanders W, Russo J Jr, et al. Transaminase elevations in patients receiving bovine or porcine heparin. Annals of Internal Medicine 100: 646–650, 1984

    PubMed  Google Scholar 

  • Edes TE, Sunderrajan EV. Heparin-induced hyperkalemia. Archives of Internal Medicine 145: 1070–1072, 1985

    Article  PubMed  CAS  Google Scholar 

  • Fagher B, Lundh B. Heparin treatment of deep vein thrombosis. Acta Medica Scandinavica 210: 357–361, 1981

    Article  PubMed  CAS  Google Scholar 

  • Fennerty A, Thomas P, Backhouse G, Bentley P, Campbell IA, Routledge PA. Audit of control of heparin treatment. British Medical Journal 290: 27–28, 1985

    Article  PubMed  CAS  Google Scholar 

  • Fernandez F, Nguyen P, van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. Haemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thrombosis Research 43: 491–495, 1986

    Article  PubMed  CAS  Google Scholar 

  • Francis CW, Marder VJ, Evarts CM, Yaukoolbodi S. Two-step warfarin therapy: prevention of postoperative venous thrombosis without excessive bleeding. Journal of the American Medical Association 249: 374–378, 1983

    Article  PubMed  CAS  Google Scholar 

  • Gallus A, Jackaman J, Tillen J, Mills W, Wyeherley A. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 2: 1293–1296, 1986

    Article  PubMed  CAS  Google Scholar 

  • Gitel SN, Wessler S. The antithrombotic effects of warfarin and heparin following infusions of tissue thromboplastin in rabbits: clinical implication. Journal of Laboratory and Clinical Medicine 94: 481–488, 1979

    PubMed  CAS  Google Scholar 

  • Glazier RL, Crowell EB. Randomized prospective trial of continuous versus intermittent heparin therapy. Journal of the American Medical Association 236: 1365–1367, 1976

    Article  PubMed  CAS  Google Scholar 

  • Goldhaber SZ, Meyerovitz MF, Green D, et al. Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. American Journal of Medicine 88: 235–240, 1990

    Article  PubMed  CAS  Google Scholar 

  • Griffith GC, Nichols G, Asher J, et al. Heparin osteoporosis. Journal of the American Medical Association 193: 91–94, 1965

    Article  PubMed  CAS  Google Scholar 

  • Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. American Journal of Medicine 68: 122–40, 1980

    Article  PubMed  CAS  Google Scholar 

  • Hattersley PG, Mitsuoka JC, King JH. Source of error in heparin therapy of thromboembolic disease. Archives of Internal Medicine 140: 1173–1175, 1980

    Article  PubMed  CAS  Google Scholar 

  • Heiden D, Mielke CH, Rodvien R. Impairment by heparin of primary hemostasis and platelet (14C) 5-hydroxytryptamine release. British Journal of Haematology 36: 427–436, 1977

    Article  PubMed  CAS  Google Scholar 

  • Hirsh J. Heparin. New England Journal of Medicine 324: 1565–1574, 1991

    Article  PubMed  CAS  Google Scholar 

  • Hirsh J, McCarthy RA, DeGruchy GC. Heparin in the treatment of venous thromboembolic disease: administration, control, and results. Medical Journal of Australia 2: 153–159, 1968

    PubMed  Google Scholar 

  • Hirsh J, van Aken WG, Gallus AS. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 153: 691–695, 1976

    Article  Google Scholar 

  • Holmgren K, Anderson G, Fagrell B, et al. One month versus six month therapy with oral anticoagulants after symptomatic deep vein thrombosis. Acta Medica Scandinavica 218: 279–284, 1985

    Article  PubMed  CAS  Google Scholar 

  • Hommes DW, Bura A, Mazzolai L, et al. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta analysis 116: 279–284, 1992

    CAS  Google Scholar 

  • Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. New England Journal of Medicine 323: 1433–1437, 1990

    Article  PubMed  CAS  Google Scholar 

  • Hull RD, Delmore TJ, Carter C, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. New England Journal of Medicine 306: 189–194, 1982

    Article  PubMed  CAS  Google Scholar 

  • Hull RD, Delmore TJ, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. New England Journal of Medicine 301: 855–858, 1979

    Article  PubMed  CAS  Google Scholar 

  • Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. New England Journal of Medicine 315: 1109–1114, 1986

    Article  PubMed  CAS  Google Scholar 

  • Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. New England Journal of Medicine 322: 1260–1264, 1990

    Article  PubMed  CAS  Google Scholar 

  • Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Archives of Internal Medicine, in press, 1992

  • Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease Chest 95: 37S–51S, 1989

    PubMed  CAS  Google Scholar 

  • International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet 336: 71–75, 1990

    Article  Google Scholar 

  • ISIS (International Studies of Infarct Survival) Pilot Study Investigators. Randomised factorial trial of high-dose streptokinase, or oral aspirin and of intravenous heparin in acute myocardial infarction. European Heart Journal 8: 634–642, 1987

    Google Scholar 

  • ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 339: 753–770, 1992

    Article  Google Scholar 

  • Jaffe MD, Willis PW III. Multiple fracture associated with long-term heparin therapy. Journal of the American Medical Association 193: 158–160, 1965

    Article  PubMed  CAS  Google Scholar 

  • Kakkar W, Howe CT, Flanc C, Clark MB. Natural history of post operative deep vein thrombosis. Lancet 2: 230–233, 1969

    Article  PubMed  CAS  Google Scholar 

  • Kanis JA. Heparin in the treatment of pulmonary thromboembolism. Thrombosis and Haemostasis 32: 517–527, 1974

    Google Scholar 

  • Kernohan RJ, Todd C. Heparin therapy in thromboembolic disease. Lancet 1: 621–623, 1966

    Article  PubMed  CAS  Google Scholar 

  • Kiil J, Kiil J, Axelsen F, et al. Prophylaxis against postoperative pulmonary embolism and deep vein thrombosis by low-dose heparin. Lancet 1: 1115–1116, 1978

    Article  PubMed  CAS  Google Scholar 

  • Lagerstedt CI, Olsson C-G, Fagher BO, Oquist BN, Albrechtsson U. Need for long term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 2: 515–518, 1985

    Article  PubMed  CAS  Google Scholar 

  • Landerfeld CS, Cook EF, Flatley M, Weisberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. American Journal of Medicine 82: 703–713, 1987

    Article  Google Scholar 

  • Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. New England Journal of Medicine 309: 396–403, 1983

    Article  PubMed  Google Scholar 

  • Leyvraz PF, Richard J, Bachmann F, et al. Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement. New England Journal of Medicine 309: 954–958, 1983

    Article  PubMed  CAS  Google Scholar 

  • Mant MJ, Thong KL, Birtwhistle RV, et al. Haemorrhagic complications of heparin therapy. Lancet 1: 1133–1135, 1977

    Article  PubMed  CAS  Google Scholar 

  • Minar E, Ehringer H, Hirschl M, et al. Transaminasenanstieg: eine weitgehend unbekannte Nebenwirkung der Heparintherapie. Deutsch Medizinische Wochenschrift 105: 1713–1717, 1980

    Article  CAS  Google Scholar 

  • Moser KM, LeMoine JR. Is embolic risk conditioned by location of deep venous thrombosis? Annals of Internal Medicine 94: 439–444, 1981

    PubMed  CAS  Google Scholar 

  • National Heart Foundation of Australia Coronary Thrombolysis Study Group. A randomized comparison of oral aspirin/dipyridamole versus intravenous heparin after rtPA for acute myocardial infarction. Circulation 80 (Suppl. II): II–114A, 1989

    Google Scholar 

  • Neri Serneri GG, Gensini GR, Poggesi L, et al. Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina. Lancet 335: 615–618, 1990

    Article  PubMed  CAS  Google Scholar 

  • Neri Serneri GG, Rovelli F, Gensini GF, Pirelli S, Carnovali M, Fortini A. Effectiveness of low-dose heparin in prevention of myocardial reinfarction. Lancet 1: 937–942, 1987

    Article  PubMed  CAS  Google Scholar 

  • Ofosu FA, Hirsh J, Esmon CT, et al. Unfractionated heparin inhibits thrombin-catalyzed amplification reactions of coagulation more efficiently than those catalyzed by factor Xa. Biochemical Journal 257: 143–150, 1989

    PubMed  CAS  Google Scholar 

  • Pini M, Pattachini C, Quintavalla R, et al. Subcutaneous vs intravenous heparin in the treatment of deep venous thrombosis — a randomized clinical trial. Thrombosis and Haemostasis 64: 222–226, 1990

    PubMed  CAS  Google Scholar 

  • Poller L, Tomson JM, Yee KF. Heparin and partial thromboplastin time: an international survey. British Journal of Haematology 44: 161–165, 1980

    Article  PubMed  CAS  Google Scholar 

  • Powers PJ, Gent M, Jay RM, et al. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Archives of Internal Medicine 149: 771–774, 1989

    Article  PubMed  CAS  Google Scholar 

  • RISC Group/Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 336: 827–830, 1990

    Article  Google Scholar 

  • Sackler JP, Liu L. Heparin-induced osteoporosis. British Journal of Radiology 46: 458–460, 1973

    Article  Google Scholar 

  • Salzman EW, Deykin D, Shapiro RM, et al. Management of heparin therapy; controlled prospective trial. New England Journal of Medicine 292: 1046–1050, 1975

    Article  PubMed  CAS  Google Scholar 

  • Saour NJ, Sieck JO, Mamo LAR, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. New England Journal of Medicine 322: 428–432, 1990

    Article  PubMed  CAS  Google Scholar 

  • SCATI (Studio sulla Calciparina nell’Angina e nella Trombosi Ventricolare nell’Infarto) Group. Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. Lancet 2: 182–186, 1989

    Google Scholar 

  • Schwartz KA, Royer G, Kaufman DB, Penner JA. Complications of heparin administration in normal individuals. American Journal of Hematology 19: 355–363, 1985

    Article  PubMed  CAS  Google Scholar 

  • Simon TL, Hyers TM, Gaston JP, Harker LA. Heparin pharmacokinetics: increased requirements in pulmonary embolism. British Journal of Haematology 39: 111–120, 1978

    Article  PubMed  CAS  Google Scholar 

  • Squires JW, Pinch LW. Heparin-induced spinal fractures. Journal of the American Medical Association 241: 2417–2418, 1979

    Article  PubMed  CAS  Google Scholar 

  • Stevenson RE, Burton OM, Ferlanto GJ, et al. Hazards of oral anticoagulants during pregnancy. Journal of the American Medical Association 243: 1549–1551, 1980

    Article  PubMed  CAS  Google Scholar 

  • Theroux P, Quimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina? New England Journal of Medicine 319: 1105–1111, 1988

    Article  PubMed  CAS  Google Scholar 

  • Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after discontinuation of heparin. New England Journal of Medicine 327: 141–145, 1992

    Article  PubMed  CAS  Google Scholar 

  • Topol EJ, George BS, Kereiakes DJ, et al. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 79: 281–286, 1989

    Article  PubMed  CAS  Google Scholar 

  • Triplett DA, Harris CS, Koepke JA. The effect of heparin on the activated partial thromboplastin time. American Journal of Clinical Pathology 70: 556–559, 1978

    PubMed  CAS  Google Scholar 

  • Turpie AGG, Robinson JG, Doyle DJ, et al. Comparison of highdose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. New England Journal of Medicine 320: 352–357, 1989

    Article  PubMed  CAS  Google Scholar 

  • The Urokinase Pulmonary Embolism Trial. A National Cooperative Study. Circulation 47 (Suppl.): 1–100, 1973

    Article  Google Scholar 

  • Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 40: 498–530, 1990

    Article  PubMed  CAS  Google Scholar 

  • Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. In Coller BS (Ed.) Progress in hemostasis and thrombosis, Vol. 10, pp. 1–34, W. B. Saunders Company, Philadelphia, 1991

    Google Scholar 

  • Wessler S, Reimer L, Freiman R, et al. Serum-induced thrombosis: studies of its induction and evolution under controlled conditions in vivo. Circulation 20: 264–274, 1959

    Article  Google Scholar 

  • Wheeler AP, Jaquiss RD, Newman JH. Physician practices in the treatment of pulmonary embolism and deep vein thrombosis. Archives of Internal Medicine 148: 1321–1325, 1988

    Article  PubMed  CAS  Google Scholar 

  • White RH, McGohan JP, Daschbach MM, Hartling RP. Diagnosis of deep vein thrombosis using duplex ultrasound. Annals of Internal Medicine 111: 297–304, 1989

    PubMed  CAS  Google Scholar 

  • White PW, Sadd Jr, Nensel RE. Thrombotic complications of heparin therapy. Annals of Surgery 190: 595–608, 1979

    Article  PubMed  CAS  Google Scholar 

  • Wilson JE III, Bynum LJ, Parkey RW. Heparin therapy in venous thromboembolism. American Journal of Medicine 70: 808–816, 1981

    Article  PubMed  Google Scholar 

  • Wilson JR, Lampman J. Heparin therapy: a randomized prospective study. American Heart Journal 97: 155–158, 1979

    Article  PubMed  CAS  Google Scholar 

  • Wise PW, Hall AJ. Heparin-induced osteopenia in pregnancy. British Medical Journal 2: 110–111, 1980

    Article  Google Scholar 

  • Yin ET, Wessler S, Butler JV. Plasma heparin: a unique, practical, submicrogram-sensitive assay. Journal of Laboratory and Clinical Medicine 81: 298–310, 1973

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pulmonology and Pulmonary Occupational Medicine, St Louis University Medical Center, 3635 Vista Avenue at Grand Boulevard, PO Box 15250, St Louis, Missouri, MO 63110-0250, USA

    Thomas M. Hyers

Authors
  1. Thomas M. Hyers
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hyers, T.M. Heparin Therapy. Drugs 44, 738–749 (1992). https://doi.org/10.2165/00003495-199244050-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199244050-00006

Keywords

Search

Navigation